Sivia Capital Partners LLC Buys Shares of 5,103 GSK plc (NYSE:GSK)

Sivia Capital Partners LLC purchased a new position in GSK plc (NYSE:GSK) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 5,103 shares of the pharmaceutical company’s stock, valued at approximately $209,000.

Other institutional investors have also made changes to their positions in the company. 1832 Asset Management L.P. grew its holdings in shares of GSK by 9.1% in the 1st quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock valued at $132,000 after buying an additional 257 shares during the period. Boltwood Capital Management grew its position in shares of GSK by 2.5% in the 2nd quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock valued at $429,000 after acquiring an additional 270 shares during the period. J.W. Cole Advisors Inc. raised its stake in GSK by 4.7% in the first quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock valued at $261,000 after buying an additional 271 shares during the period. First Affirmative Financial Network lifted its holdings in GSK by 4.7% during the 2nd quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock valued at $245,000 after purchasing an additional 283 shares during the last quarter. Finally, Chapin Davis Inc. grew its stake in GSK by 2.2% in the 1st quarter. Chapin Davis Inc. now owns 14,231 shares of the pharmaceutical company’s stock valued at $610,000 after buying an additional 300 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at GSK

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the company’s stock in a transaction on Friday, September 27th. The shares were acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

GSK Stock Performance

Shares of GSK opened at $39.13 on Tuesday. The company has a market cap of $81.10 billion, a PE ratio of 14.18, a P/E/G ratio of 1.30 and a beta of 0.65. GSK plc has a one year low of $33.67 and a one year high of $45.92. The stock has a 50-day moving average of $41.49 and a 200-day moving average of $41.34. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping the consensus estimate of $1.00 by $0.09. The firm had revenue of $9.95 billion during the quarter, compared to the consensus estimate of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. On average, equities research analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Investors of record on Friday, August 16th were issued a dividend of $0.3843 per share. This represents a $1.54 dividend on an annualized basis and a yield of 3.93%. The ex-dividend date of this dividend was Friday, August 16th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 55.80%.

Analysts Set New Price Targets

Several research firms recently commented on GSK. Jefferies Financial Group upped their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Citigroup raised shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Berenberg Bank upgraded GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $50.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.